Search Our Scientific Publications & Authors

J Am Acad Dermatol 2021 May 27. Epub 2021 May 27.

Service de Médecine Interne, Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), APHP-CUP, Hôpital Cochin, F-75014 Paris, Université de Paris, France.

Rheumatol Int 2021 May 19. Epub 2021 May 19.

Department of Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece.

Key Message: RTX could be an effective and safe alternative treatment for refractory EF. Rituximab (RTX) is a successful therapeutic option for various autoimmune diseases. Our aim is to report our experience with RTX in eosinophilic fasciitis (EF) and review published data on its efficacy for the treatment of EF. Read More

Joint Bone Spine 2021 Apr 20;88(5):105189. Epub 2021 Apr 20.

Rheumatology Unit, Hospital Universitario Ramón y Cajal, Carretera de Colmenar Viejo, 9,1 km, 28034 Madrid, Spain.

Int J Rheum Dis 2021 May 22;24(5):721-723. Epub 2021 Apr 22.

Division of Rheumatology, Mayo Clinic, Jacksonville, FL, USA.

J Am Acad Dermatol 2021 Apr 2. Epub 2021 Apr 2.

Division of Dermatology, University of Toronto, Toronto, Canada; Faculty of Medicine, University of Toronto, Toronto, Canada; Probity Medical Research, Waterloo, Canada. Electronic address:

Medicine (Baltimore) 2021 Apr;100(13):e25359

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.

Rationale: Eosinophilic fasciitis (EF) is an uncommon connective tissue disorder characterized by limb and trunk erythema, with symmetrical thickening of the skin. Its pathogenesis is poorly understood. Treatment consists mainly of glucocorticoids. Read More

J Osteopath Med 2021 03 30;121(6):555-559. Epub 2021 Mar 30.

Department of Dermatology, Keesler Medical Center, Biloxi, MS, USA.

This case report highlights the potentially underrecognized subtype of unilateral eosinophilic fasciitis (EF) in a 28 year old man. With fewer than 300 reported encounters to date, EF is a rare disease that eludes clinicians by presenting as a scleroderma like syndrome. As EF remains a clinical diagnosis, biopsy results may be nonspecific, and the disease can easily be misdiagnosed (or missed entirely) if a full thickness biopsy is not reviewed by a dermatopathologist. Read More

J Med Life 2021 Jan-Mar;14(1):121-124

Department of Gastroenterology, Bucharest Emergency University Hospital.

This case report describes a rare case of progressive muscle weakness in a patient treated for eosinophilic fasciitis (EF) for many years before being diagnosed with a second autoimmune disease: dermatomyositis. Our case is a report of a 65-year-old male diagnosed with eosinophilic fasciitis 7 years before being evaluated in our service at Mayo Clinic in Jacksonville, Florida, due to progressive muscle weakness despite the chronic treatment with methotrexate. Contrast-enhanced magnetic resonance imaging of the lower extremity showed enhancement throughout the thigh musculature, which led us to pursue biopsies of the fascia and muscle in order to confirm the diagnosis of EF associated with myopathy. Read More

J Med Case Rep 2021 Mar 15;15(1):135. Epub 2021 Mar 15.

Department of Hematology and Cell Therapy, University Hospital of Tours, 2 Boulevard Tonnellé, 37044, Tours Cedex 9, France.

Background: Shulman's disease, or eosinophilic fasciitis (EF), is a rare autoimmune disease, characterized by sclerodermic skin lesions with progressive induration and thickening of the soft tissues. Chronic graft-versus-host-disease (GVHD) presenting as EF is a very rare manifestation of cutaneous GVHD.

Case Presentation: We report an unusual case of EF in a 46-year-old Caucasian male patient who had received an allogenic hematopoietic stem cell transplantation in the context of relapsed/refractory multiple myeloma. Read More

Reumatismo 2021 Jan 18;72(4):252-254. Epub 2021 Jan 18.

Department of Internal Medicine, Groupe Hospitalier Sud Ile de France, Melun.

Eosinophilic fasciitis is a rare connective tissue disease with a clinical presentation of scleroderma-like disease. We report a case of a 36-year-old female patient with a 6-month history of progressive stiffness involving her forearms and legs with joint pain. Laboratory examinations showed hypereosinophilia and elevated C-reactive protein. Read More

J Dermatolog Treat 2021 Feb 21:1-4. Epub 2021 Feb 21.

Rheumatology Department, Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico.

Eosinophilic fasciitis (EF) is an uncommon autoimmune connective tissue disorder characterized by edema, erythema, and subsequent induration of the extremities. It is commonly treated with corticosteroids but there is no treatment ladder for immunosuppressants or steroid-sparing agents. We report two EF cases treated effectively with mycophenolate mofetil (MMF) or mycophenolic acid (MPA) and present a literature review. Read More

Indian J Dermatol Venereol Leprol 2021 Jan-Feb;87(1):146

Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.

Rheumatol Int 2021 Jan 23. Epub 2021 Jan 23.

Internal Medicine Department, Hospital Regional Universitario de Málaga, Málaga, Spain.

Eosinophilic fasciitis (EF) is characterized by symmetrical thickening of subcutaneous muscular fascia, causing skin induration with wrinkles and prominent hair follicles: the classic peau d'orange. Eosinophilia is a characteristic-albeit not universal-finding. We present the case of a 43-year-old pregnant woman diagnosed with EF during pregnancy who had extensive cutaneous involvement and severe functional repercussions, including worsening of lung function and intrauterine growth restriction as a possible complication. Read More

Eur J Nucl Med Mol Imaging 2021 06 18;48(6):2049-2050. Epub 2021 Jan 18.

Department of Biophysics and Nuclear Medicine-Molecular Imaging, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.

Acta Dermatovenerol Croat 2020 Dec;28(3):190-192

Monika Bilewicz-Stebel, MD, Department of Internal Medicine, Dermatology and Allergology, Curie-Skłodowskiej 10, 41-800 Zabrze, Poland;

Eosinophilic fasciitis is a rare disease from the group of scleroderma-like connective tissue diseases with unclear etiopathogenesis. It may be occasionally accompanied with other eosinophilic or autoimmune dysfunctions (1,2). Lack of international diagnostic criteria and treatment consensus may lead to diagnostic and therapeutic difficulties. Read More

JAAD Case Rep 2021 Jan 25;7:110-112. Epub 2020 Nov 25.

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

Clin Case Rep 2020 Dec 15;8(12):3545-3546. Epub 2020 Jul 15.

Department of Nephrology and Rheumatology University Medical Center Göttingen Göttingen Germany.

Clinical examination can be the key to pursuing a diagnosis, even in rare diseases. The "groove sign" is a typical finding in eosinophilic fasciitis and can be elicited by elevation of the arm to allow for venous return with visible "grooving" of the veins due to skin thickening. Read More

J Cosmet Dermatol 2020 Dec 23. Epub 2020 Dec 23.

Medical Faculty, Department of Dermatology and Venereology, Ege University, Izmir, Turkey.

Background: Nivolumab is one of the targeted cancer therapy agent that acts to increase the immune responses by inhibition of antiprogrammed-death-receptor 1, which is one of the check points of the immune response. Nivolumab can be used to treat malign melanoma, lung, renal, head and neck, colorectal, hepatocellular cancers, and special cases of Hodgkin lymphoma.

Aims: We aimed to report a rarer cutaneous side effect of nivolumab because of the increasing uses of this agent in various cancer treatments. Read More

JAAD Case Rep 2020 Dec 25;6(12):1303-1306. Epub 2020 Apr 25.

Auxilio Mutuo Hospital, San Juan, Puerto Rico.

J Am Acad Dermatol 2020 Nov 11. Epub 2020 Nov 11.

Unité de soins et de recherche en médecine interne et de maladies infectieuses, Hôpital Européen, Marseille, France.

Indian J Dermatol 2020 Sep-Oct;65(5):427-429

Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran. E-mail:

Rheumatology (Oxford) 2021 Mar;60(3):e107-e108

Rheumatic Diseases Unit, Western General Hospital, Edinburgh, UK.

Rheumatol Ther 2020 Dec 16;7(4):1045-1052. Epub 2020 Oct 16.

Division of Rheumatology, Department of Internal Medicine, University of Patras Medical School, Patras, Greece.

Immune checkpoint inhibitors are a promising new therapeutic strategy in oncology that aims to eliminate cancer cells by enhancing patients' immune response against tumor antigens. Despite their beneficial effects, immune checkpoint inhibitors are also responsible for a plethora of autoimmune manifestations, known as immune-related adverse events. We present a case of eosinophilic fasciitis-like disorder in an 81-year-old patient treated with the programmed death cell protein 1 inhibitor pembrolizumab for non-small-cell lung cancer. Read More

J Clin Rheumatol 2020 Sep 23. Epub 2020 Sep 23.

From the Department of Internal Medicine III, Jena University Hospital-Friedrich-Schiller-University Jena, Jena.

Clin Rheumatol 2021 Jun 24;40(6):2477-2483. Epub 2020 Sep 24.

First Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuokashimoaizuki, Eiheiji, Fukui, 910-1193, Japan.

Eosinophilic fasciitis (EF) is a rare connective tissue disease that causes inflammation and fibrosis of the fascia, inducing pain and motor dysfunction. Characteristic skin manifestations, such as edema, erythema, induration, peau d'orange appearance, and the groove sign, are of diagnostic significance and observed in the majority of patients with EF. We herein report a case of EF without these characteristic skin manifestations. Read More

Pediatr Dermatol 2020 Nov 24;37(6):1171-1172. Epub 2020 Sep 24.

Department of Dermatology, Stanford University, Palo Alto, California, USA.

Eosinophilic fasciitis (EF) is a rare condition in children that is typically treated with systemic corticosteroids. We present the case of a 9-year-old boy with biopsy-proven EF, refractory to systemic corticosteroids and methotrexate. The tyrosine kinase inhibitor imatinib was added as adjuvant therapy, leading to improvement in joint function and skin laxity. Read More

Rheumatology (Oxford) 2021 Mar;60(3):1113

Department of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey.

Chin Med J (Engl) 2020 Sep 10;134(5):616-618. Epub 2020 Sep 10.

Department of Dermatology, Chinese Academy of Medical Sciences, Peking Union Medical College, Peking Union Medical College Hospital, Beijing 100730, China.

JAAD Case Rep 2020 Sep 31;6(9):951-953. Epub 2020 Jul 31.

Department of Rheumatology, Kaiser Permanente, South Sacramento, California.

Neurology 2020 10 10;95(15):695-697. Epub 2020 Sep 10.

From the Department of Rheumatology (L.A.S., A.A.G., O.F.), St Vincent's University Hospital, Elm Park, Dublin, Ireland; Department of Pathology (N.S.), St Vincent's University Hospital, Elm Park, Dublin, Ireland; Department of Endocrinology (D.O.S.); and Department of Neurology (C.M., M.H.), St Vincent's University Hospital, Elm Park, Dublin, Ireland.